A separate Hagens Berman investigation and pending class action focus on whether Grail misled investors about the NHS-Galleri trial’s design, data and ability to show a statistically significant late-stage cancer reduction within three years.
Litigation over GRAIL, Inc. has widened after Hagens Berman said it is investigating claims in a pending class action alleging violations of U.S. securities laws tied to the company’s disclosures about the NHS-Galleri cancer screening trial. The matter builds on Grail’s February 19, 2026 announcement that the trial failed to meet its primary endpoint of a statistically significant reduction in late-stage, Stage III and IV, cancer diagnoses, which the company said may have reflected the need for a longer follow-up period. Hagens Berman said the complaint covers a class period of May 13, 2025 through February 19, 2026 and alleges Grail repeatedly portrayed the trial as robust and appropriately designed for a three-year follow-up even as internal data trends allegedly suggested that timeframe was insufficient. The firm also said investors allege Grail selectively highlighted favorable top-line results while withholding more granular data that could have indicated a lower probability of success. Grail’s share price fell about 50.55% in one day after the February disclosure, wiping out more than $2.2 billion in market value, according to the Hagens Berman announcement. Investors seeking lead-plaintiff status in the litigation face an August 4, 2026 deadline.